Could a drug cocktail shrink sarcomas before surgery?
NCT ID NCT05167994
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving a drug called anlotinib (which cuts off tumor blood supply) along with immunotherapy (penpulimab) and radiation before surgery can improve outcomes for people with soft tissue sarcoma in the arms, legs, or trunk. The study will enroll 30 adults and focus on safety, wound complications, and quality of life. It is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anlotinib hydrochloride (a drug that blocks blood vessel growth) and penpulimab (an immunotherapy drug)
What this could lead to
If successful, this combination could improve tumor shrinkage before surgery and reduce wound complications for people with soft tissue sarcoma.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply widely. The combination may increase side effects like wound healing problems or toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••